Compare Mongodb Inc (MDB) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mongodb Inc vs Moderna, Inc. — how do they compare? Mongodb Inc trades at $374.06 (market cap $29.24B), while Moderna, Inc. trades at $197.5 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 2.7× Mongodb Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Mongodb Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mongodb Inc for 45 Days and Moderna, Inc. for 59 Days on average.
| MDB | MRNA | |
|---|---|---|
Market Cap | $29.24B | $78.65B |
Volume | 1,304,995 | 37,373,437 |
Sector | Technology | Health |
52-Week High | $472.29 | $203.46 |
52-Week Low | $225.95 | $22.36 |
Typical Hold Time | 45 Days | 59 Days |
Enterprise Value | $26.86B | $74.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MongoDB (MDB) trades at $363.03, up 0.64% today, amid a bearish technical signal despite recent earnings beats. The stock faces headwinds with a high P/E of 511.31 and negative net income, though revenue growth remains strong, reaching $2.01B in 2025. Recent news highlights AI product launches and a CEO transition, with investor sentiment mixed following a sharp sell-off.
Outlook: Long-term growth potential exists with raised AI-focused targets, but high valuation and profitability challenges pose risks. Analyst consensus is bullish with an $456.76 price target, yet technical indicators and cash flow volatility warrant caution for near-term volatility.
Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.
While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
